Thursday was a huge day for deal makers — especially those at smaller boutique shops.
Four big transactions were announced, including Abbott Labs’ $25 billion deal for St. Jude Medical, AbbVie’s $5.8 billion deal for Stemcentrx, Sanofi’s unsolicited $9.3 billion bid for Medivation, and NBCUniversal’s $3.8 billion deal for DreamWorks.
Among the banks that can expect big winnings in fees are Evercore, Guggenheim Securities, and Centerview Partners.
Morgan Stanley also had a big day, advising both Stemcentrx and Sanofi.
Here’s the breakdown of advisers, with the independent advisory shops highlighted:
Abbott Labs — St. Jude Medical
- Abbott: Evercore (lead adviser) and Bank of America Merrill Lynch
- St. Jude: Guggenheim Securities
AbbVie — Stemcentrx
- Stemcentrx: Morgan Stanley
Sanofi — Medivation
- Sanofi: Morgan Stanley
- Medivation: Evercore and JPMorgan
NBCUniversal — DreamWorks
- DreamWorks: Centerview Partners
Boutique banks have been taking big deals from their larger rivals in the last couple of years. Three boutiques — Evercore, Centerview, and Moelis — ranked in the top 15 banks for global M&A revenue in the first quarter.
Moelis, for its part, just reported a killer first quarter, with record revenues, up 27% from last year.
Evercore lists around 80 senior managing directors (MD) in corporate advisory globally on its website. At Centerview, meanwhile, there are 30 partners listed on the website.
NOW WATCH: Money & Markets videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.